Roche RHHBY announced positive results from the late-stage STARGLO on the blood cancer drug Columvi (glofitamab). The STARGLO study is a phase III, multicentre, open-label, randomized study evaluating...
Source LinkRoche RHHBY announced positive results from the late-stage STARGLO on the blood cancer drug Columvi (glofitamab). The STARGLO study is a phase III, multicentre, open-label, randomized study evaluating...
Source Link
Comments